Tandem Diabetes Care’s (TNDM) “Buy” Rating Reiterated at Canaccord Genuity Group
Canaccord Genuity Group reaffirmed their buy rating on shares of Tandem Diabetes Care (NASDAQ:TNDM – Free Report) in a research report report published on Wednesday,Benzinga reports. The firm currently has a $63.00 target price on the medical device company’s stock. A number of other research firms also recently commented on TNDM. Morgan Stanley upgraded Tandem […]
Canaccord Genuity Group reaffirmed their buy rating on shares of Tandem Diabetes Care (NASDAQ:TNDM – Free Report) in a research report report published on Wednesday,Benzinga reports. The firm currently has a $63.00 target price on the medical device company’s stock. A number of other research firms also recently commented on TNDM. Morgan Stanley upgraded Tandem […]